DrugPatentWatch Database Preview
Ipilimumab - Biologic Drug Details
Summary for ipilimumab
| Tradenames: | 1 |
| Patents: | 125 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
Pharmacology for ipilimumab
| Mechanism of Action | CTLA-4-directed Antibody Interactions |
| Physiological Effect | Increased T Lymphocyte Activation |
US Patents for ipilimumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | ➤ Sign Up | OP NANO CO., LTD. (Taipei, TW) TRENDMED CO., LTD. (Beitou Dist., Taipei, TW) | ➤ Sign Up | RX | search | |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | ➤ Sign Up | H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) | ➤ Sign Up | RX | search | |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | ➤ Sign Up | University of Georgia Research Foundation, Inc. (Athens, GA) | ➤ Sign Up | RX | search | |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | ➤ Sign Up | Amgen Inc. (Thousand Oaks, CA) | ➤ Sign Up | RX | search | |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | ➤ Sign Up | AbbVie Stemcentrx LLC (North Chicago, IL) | ➤ Sign Up | RX | search | |
| Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | ➤ Sign Up | SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) | ➤ Sign Up | RX | search | |
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Patent Expiration | Status | Orphan | Source |
International Patents for ipilimumab
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Chile | 2016001716 | ➤ Sign Up |
| Cyprus | 1118232 | ➤ Sign Up |
| European Patent Office | 2970433 | ➤ Sign Up |
| Russian Federation | 2481336 | ➤ Sign Up |
| Poland | 2396036 | ➤ Sign Up |
| Japan | 6192776 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for ipilimumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017 00004 | Denmark | ➤ Sign Up | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG TENOFOVIRALAFENAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
| 16/061 | Ireland | ➤ Sign Up | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119 |
| 90001-0 | Sweden | ➤ Sign Up | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REG. NO/DATE: EU/1/15/1061 20151123 |
| 15C/058 | Belgium | ➤ Sign Up | PRODUCT NAME: COBICISTAT; AUTHORISATION NUMBER AND DATE: EU/1/13/830/001 |
| /2016 | Austria | ➤ Sign Up | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND TENOFOVIR ALAFENAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE TENOFOVIR ALAFENAMID FUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 (MITTEILUNG) 20151123 |
| 354 | Luxembourg | ➤ Sign Up | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ALAFENAMIDE DE TENOFOVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE D'ALAFENAMIDE DE TENOFOVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1061 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
